Replies to post #9268 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

$33.8M is not a lot for a biotech firm, but ARTH is not a biotech firm. AC5 is a medical device, a wound dressing. The title 'biotechnology firm' in ARTH self description has no regulatory or scientific ssignificance.

[GrosPied]

Interesting. I thought Norchi said the reason they started the company in an unusual way (some auto parts related company?? in Nevada or something equally odd) was due to a lack of financing because of the 08-09 crash. That's why the timeline seems longer than 6 years. In 2013, the market was booming with plenty of financing available.


Does this help with the timeline?
"Terrence W. Norchi, MD, our co-founder, serves as our President and Chief Executive Officer, and he is a director on our Board of Directors. Dr. Norchi has served in similar positions since co-founding ABS, our predecessor company in 2006."